Midi

Tirzepatide Safety Sheet

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Midi Tirzepatide bottle

Formulation: Tirzepatide/Glycine

Dose & Frequency: Subcutaneous injection; flexible dosing guided by side effects and weight loss trajectory.

Mechanism of Action

Dual GIP/GLP-1 receptor agonist:

  • Increases insulin secretion
  • Decreases glucagon secretion
  • Slows gastric emptying
  • Enhances satiety

Ingredients

  • Tirzepatide (FDA-registered source)
  • Glycine
  • Sodium Phosphate Dibasic
  • Sodium Chloride
  • Benzyl Alcohol
  • Diluted Hydrochloric Acid (pH adjustment)
  • Sodium Hydroxide (pH adjustment)

Clinical Benefits

  • Significant weight loss (avg. 21% body weight)
  • Improved cardiometabolic markers
  • Supports durable weight maintenance after dose reduction
  • Cardiovascular event reduction in at-risk patients

Cautions

  • Hypersensitivity to tirzepatide
  • Personal/family history of MTC or MEN2
  • Pregnancy or breastfeeding
  • Active pancreatitis or gallbladder disease
  • Eating disorders (anorexia, bulimia, orthorexia, binge eating)
  • Suicidality or psychiatric history
  • Severe GI conditions (e.g., gastroparesis)
  • Diabetic retinopathy
  • Kidney impairment or dehydration risk
  • History of tachyarrhythmias

Common Side Effects

  • Nausea, vomiting, diarrhea, constipation
  • Dyspepsia, decreased appetite, abdominal pain
  • Elevated serum amylase/lipase

Serious Risks

  • Thyroid C-cell tumors (black box warning)
  • Pancreatitis
  • Gallbladder disease
  • Acute kidney injury
  • Hypoglycemia (esp. when used with insulin or sulfonylureas)

Administration and Handling

Important: Always follow the package directions and dosing schedule provided by the pharmacy and by your prescriber.

  • Administer as a weekly subcutaneous injection (into the fatty tissue under the skin)
  • Rotate injection sites: outer upper arm, front of thigh, or abdomen (avoiding a 2-inch area around the navel)
  • Use clean hands and sanitize the injection site with alcohol
  • Do not use if the solution is cloudy, discolored, or contains particles
  • Store in the refrigerator (36–46°F) and discard 28 days after first use
  • Dispose of needles in a designated sharps container, a rigid, puncture-resistant plastic bin with a tight-fitting lid, sold at most pharmacies.

Serious side effects– Seek Medical Help

  • Lump in the neck, persistent hoarseness, or trouble swallowing
  • Rapid heartbeat or fainting
  • Changes in vision
  • Severe abdominal pain (possible pancreatitis)
  • Signs of low blood sugar (shakiness, sweating, confusion)
  • Worsening depression or new thoughts of self-harm
  • Allergic reactions (rash, itching, swelling, dizziness, difficulty breathing)

If an overdose is suspected, contact your local poison control center at 1-800-222-1222 or go to the nearest emergency room.

You may report side effects to the FDA at 1-800-FDA-1088.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medication or any other medication. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient.

This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this medicine. It does not include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine.